Please assess the completion status of the following clinical trial:

Trial Title: PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females diagnosed with type 1 diabetes mellitus for at least 24 months~* Current usage of subcutaneous insulin pump treatment~* Age 18-65 years~* C-peptide level \< 0.5 ng/ml~* Willingness to follow all study procedures, including attending all clinic visits~* Subject has provided informed consent and has signed and dated an informed consent form before any trial-related activities~Exclusion Criteria:~* Pregnant and/ or Lactating: For women of childbearing potential: there is a requirement for a negative urine pregnancy test and for agreement to use contraception during the study and for at least 1 month after participating in the study.~* HbA1c \>10.0%~* Renal insufficiency (serum creatinine of 1.2 mg/dL or greater)~* Serum ALT or AST equal to or greater than 3 times the upper limit of normal; hepatic synthetic insufficiency as defined as a serum albumin of less than 3.0 g/dL; or serum bilirubin of over 2.0.~* Hematocrit of less than or equal to 34%~* Congestive heart failure, NYHA class II, III or IV~* History of coronary artery disease~* Active foot ulceration~* History of a cerebrovascular accident~* Active alcohol abuse or substance abuse~* Active malignancy, except basal cell or squamous cell skin cancers~* Major surgical operation within 30 days prior to screening~* Seizure disorder~* Current administration of oral or parenteral corticosteroids~* Use of an investigational drug within 30 days prior to screening~* Bleeding disorder, treatment with warfarin, or platelet count below 50,000~* Proliferative or severe non-proliferative retinopathy~* Gastroparesis~* Personal or family history of pheochromocytoma or disorder with increased risk of pheochromocytoma (MEN 2, neurofibromatosis, or Von Hippel-Lindau disease)~* Insulinoma~* Allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products.~* Glycogen storage disease~* Any concurrent illness, other than diabetes, that is not controlled by a stable therapeutic regimen~* Whole blood donation of 1 pint (500 mL) within 8 weeks prior to Screening.~* Any reason the principal investigator deems exclusionary

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G-Pump™ (glucagon infusion) (Type: EXPERIMENTAL): G-Pump™ (glucagon infusion); single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
- Novo Nordisk GlucaGen® (Type: ACTIVE_COMPARATOR): Novo Nordisk GlucaGen®; single subcutaneous infusion doses 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).